Literature DB >> 12811491

Prevalence and burden of overactive bladder in the United States.

W F Stewart1, J B Van Rooyen, G W Cundiff, P Abrams, A R Herzog, R Corey, T L Hunt, A J Wein.   

Abstract

CONTEXT: the National Overactive BLadder Evaluation (NOBLE) Program was initiated to better understand the prevalence and burden of overactive bladder in a broad spectrum of the United States population.
OBJECTIVE: to estimate the prevalence of overactive bladder with and without urge incontinence in the US, assess variation in prevalence by sex and other factors, and measure individual burden.
DESIGN: US national telephone survey using a clinically validated interview and a follow-up nested study comparing overactive bladder cases to sex- and age-matched controls.
SETTING: noninstitutionalized US adult population. PARTICIPANTS: a sample of 5,204 adults >/=18 years of age and representative of the US population by sex, age, and geographical region. MAIN OUTCOME MEASURES: prevalence of overactive bladder with and without urge incontinence and risk factors for overactive bladder in the US. In the nested case-control study, SF-36, CES-D, and MOS sleep scores were used to assess impact.
RESULTS: the overall prevalence of overactive bladder was similar between men (16.0%) and women (16.9%), but sex-specific prevalence differed substantially by severity of symptoms. In women, prevalence of urge incontinence increased with age from 2.0% to 19% with a marked increase after 44 years of age, and in men, increased with age from 0.3% to 8.9% with a marked increase after 64 years of age. Across all age groups, overactive bladder without urge incontinence was more common in men than in women. Overactive bladder with and without urge incontinence was associated with clinically and significantly lower SF-36 quality-of-life scores, higher CES-D depression scores, and poorer quality of sleep than matched controls.
CONCLUSIONS: the NOBLE studies do not support the commonly held notion that women are considerably more likely than men to have urgency-related bladder control problems. The overall prevalence of overactive bladder does not differ by sex; however, the severity and nature of symptom expression does differ. Sex-specific anatomic differences may increase the probability that overactive bladder is expressed as urge incontinence among women compared with men. Nonetheless, overactive bladder, with and without incontinence, has a clinically significant impact on quality-of-life, quality-of-sleep, and mental health, in both men and women.

Entities:  

Mesh:

Year:  2002        PMID: 12811491     DOI: 10.1007/s00345-002-0301-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  530 in total

1.  Prevalence and predictors of overactive bladder in nonpregnant nulliparous women below 65 years of age.

Authors:  Dudley Robinson; Sigvard Åkervall; Adrian Wagg; Christopher Chapple; Ian Milsom; Maria Gyhagen
Journal:  Int Urogynecol J       Date:  2017-08-04       Impact factor: 2.894

2.  Parity is not associated with urgency with or without urinary incontinence.

Authors:  Annemarie G Hirsch; Vatche A Minassian; Anne Dilley; Jennifer Sartorius; Walter F Stewart
Journal:  Int Urogynecol J       Date:  2010-05-11       Impact factor: 2.894

Review 3.  [Use of botulinum toxin type A in non-neurogenic overactive bladder. Recommendations of the Working Group Urological Functional Diagnostics and Urology in Women].

Authors:  R M Bauer; C Seif; T Bschleipfer; A Reitz; D Schultz-Lampel
Journal:  Urologe A       Date:  2015-03       Impact factor: 0.639

4.  Acupuncture for overactive bladder in female adult: a randomized controlled trial.

Authors:  Zhengyong Yuan; Changxiao He; Shibing Yan; Donglai Huang; Hanhui Wang; Wei Tang
Journal:  World J Urol       Date:  2014-11-16       Impact factor: 4.226

Review 5.  The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Authors:  Karl-Erik Andersson; Nurul Choudhury; Jean-Nicolas Cornu; Moses Huang; Cees Korstanje; Emad Siddiqui; Philip Van Kerrebroeck
Journal:  Ther Adv Urol       Date:  2018-07-06

6.  Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.

Authors:  Sender Herschorn; Jameel Nazir; Barbara Ramos; Zalmai Hakimi
Journal:  Can Urol Assoc J       Date:  2017 Mar-Apr       Impact factor: 1.862

7.  Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela R Paraiso; Shawn A Menefee; Joseph Schaffer; Jerry Lowder; Salil Khandwala; Larry Sirls; Cathie Spino; Tracy L Nolen; Dennis Wallace; Susan F Meikle
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

8.  Clinical validation of the Bladder Health Survey for urinary incontinence in a population sample of women.

Authors:  Vatché A Minassian; Xiaowei S Yan; Haiyan Sun; Raissa O Platte; Walter F Stewart
Journal:  Int Urogynecol J       Date:  2015-09-19       Impact factor: 2.894

9.  [Prevalence of urinary incontinence in the German population].

Authors:  M E Beutel; A Hessel; R Schwarz; E Brähler
Journal:  Urologe A       Date:  2005-03       Impact factor: 0.639

Review 10.  Trospium chloride in the management of overactive bladder.

Authors:  Eric S Rovner
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.